id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S8694 R29315 |
Tomson (Phenobarbital or Primidone), 2018 | Neural tube defects | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 17.21 [1.56;190.41] C | 2/294 1/2,514 | 3 | 294 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8656 R29148 |
Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 | Neural tube defects | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 1.57 [0.08;32.85] C | 0/199 2/1,562 | 2 | 199 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8671 R29200 |
Bànhidy (Phenobarbital or Primidone), 2011 | Neural tube defects | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 1.46 [0.03;83.47] C | 0/6 1/11 | 1 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8673 R29215 |
Canger (Phenobarbital or Primidone), 1999 | Neural tube defects | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.21 [0.00;10.77] C | 0/118 0/25 | 0 | 118 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 2.60 [0.40;17.05] | 6 | 617 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital or Primidone; 2: Phenobarbital) (Controls exposed to Lamotrigine, sick; 3: Phenobarbital or Primidone; 4: Phenobarbital or Primidone;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded